X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ALEMBIC PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ALEMBIC PHARMA AUROBINDO PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 19.8 18.8 105.2% View Chart
P/BV x 3.9 4.8 81.8% View Chart
Dividend Yield % 0.3 0.7 45.1%  

Financials

 AUROBINDO PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ALEMBIC PHARMA
Mar-18
AUROBINDO PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs809645 125.4%   
Low Rs504470 107.3%   
Sales per share (Unadj.) Rs281.1166.1 169.2%  
Earnings per share (Unadj.) Rs41.421.9 188.9%  
Cash flow per share (Unadj.) Rs50.927.5 185.1%  
Dividends per share (Unadj.) Rs2.504.00 62.5%  
Dividend yield (eoy) %0.40.7 53.1%  
Book value per share (Unadj.) Rs199.4117.8 169.3%  
Shares outstanding (eoy) m585.88188.52 310.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.4 69.6%   
Avg P/E ratio x15.925.5 62.4%  
P/CF ratio (eoy) x12.920.3 63.6%  
Price / Book Value ratio x3.34.7 69.6%  
Dividend payout %6.018.3 33.1%   
Avg Mkt Cap Rs m384,630105,090 366.0%   
No. of employees `00017.3NA-   
Total wages/salary Rs m21,3086,228 342.1%   
Avg. sales/employee Rs Th9,500.7NM-  
Avg. wages/employee Rs Th1,229.4NM-  
Avg. net profit/employee Rs Th1,397.9NM-  
INCOME DATA
Net Sales Rs m164,66631,308 526.0%  
Other income Rs m1,02070 1,450.6%   
Total revenues Rs m165,68631,378 528.0%   
Gross profit Rs m37,7186,431 586.5%  
Depreciation Rs m5,5801,055 529.1%   
Interest Rs m77734 2,285.9%   
Profit before tax Rs m32,3805,413 598.2%   
Minority Interest Rs m310-   
Prior Period Items Rs m0-81 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1831,204 679.9%   
Profit after tax Rs m24,2294,128 586.9%  
Gross profit margin %22.920.5 111.5%  
Effective tax rate %25.322.2 113.7%   
Net profit margin %14.713.2 111.6%  
BALANCE SHEET DATA
Current assets Rs m121,87818,247 667.9%   
Current liabilities Rs m86,80611,235 772.6%   
Net working cap to sales %21.322.4 95.1%  
Current ratio x1.41.6 86.4%  
Inventory Days Days13086 151.8%  
Debtors Days Days6861 111.4%  
Net fixed assets Rs m81,03720,035 404.5%   
Share capital Rs m586377 155.4%   
"Free" reserves Rs m116,21821,824 532.5%   
Net worth Rs m116,80422,201 526.1%   
Long term debt Rs m4,5125,000 90.2%   
Total assets Rs m211,05239,411 535.5%  
Interest coverage x42.7160.2 26.6%   
Debt to equity ratio x00.2 17.2%  
Sales to assets ratio x0.80.8 98.2%   
Return on assets %11.810.6 112.2%  
Return on equity %20.718.6 111.6%  
Return on capital %27.419.7 138.7%  
Exports to sales %046.4 0.0%   
Imports to sales %010.5 0.0%   
Exports (fob) Rs mNA14,535 0.0%   
Imports (cif) Rs mNA3,288 0.0%   
Fx inflow Rs m80,72714,722 548.4%   
Fx outflow Rs m34,7007,026 493.9%   
Net fx Rs m46,0277,696 598.1%   
CASH FLOW
From Operations Rs m19,5483,124 625.7%  
From Investments Rs m-19,570-8,844 221.3%  
From Financial Activity Rs m8,6425,026 171.9%  
Net Cashflow Rs m8,922-693 -1,286.9%  

Share Holding

Indian Promoters % 54.1 74.1 73.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 2.9 274.1%  
FIIs % 27.7 9.1 304.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 13.9 73.4%  
Shareholders   69,601 49,328 141.1%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   FULFORD INDIA  SUVEN LIFESCIENCES  STERLING BIOTECH  WOCKHARDT  VENUS REMEDIES  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend; Sensex Ends 495 Points Lower(Closing)

Indian share markets witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 22, 2019 03:33 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - SANOFI INDIA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS